Joshua Weiyuan Wang, Ph.D., is currently the Founder and CEO of VerImmune Inc which was founded in 2020. VerImmune is a biotechnology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection. This utilizes a proprietary virus-inspired particle (ViP) platform that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors. At VerImmune, Dr. Wang led the team, raising ~$14.5M cumulatively thus far from investors and securing pharma partnerships with globally recognized pharmaceutical companies such as Janssen Biologics and Fosun Pharmaceuticals. Prior to VerImmune, Dr Wang co-founded PathoVax LLC, with Weijie Poh, Ph.D. (a fellow pathobiology student) to accelerate the commercialization of PathoVax’s HPV vaccine technology, which was related to his doctoral thesis. In this previous role as co-founder and Chief Scientific Officer of PathoVax, he managed numerous collaborative research and business initiatives towards impactful clinical solutions. During his time at PathoVax, he led or supported over $10M in funding from early stage investors/angels or non-dilutive research funding.